This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Wilson Disease (Hepatolenticular Degeneration)

ItemDetails
A. Classification codesICD-10: E83.0 (disorders of copper metabolism) | Special Copayment Reduction: V119
B. SynonymsHepatolenticular degeneration, Wilson-Kovalev disease, copper overload disease
C. Adult onsetPossibility of first manifestation in adulthood: high — Wilson disease can manifest at any age after 5 years, and neuropsychiatric symptoms commonly first appear in the 20s-40s. In some patients, initial symptoms appear even after the 50s, so differentiation is essential in adult internal medicine and neurology.
1. History1902 description of the corneal pigment ring by Kayser and 1903 by Fleischer; 1912 definition of hepatolenticular degeneration by Wilson; 1993 identification of the ATP7B gene
2. CausesATP7B gene variants → loss of function of hepatocyte copper-transporting ATPase (ATP7B) → impaired biliary copper excretion → copper accumulation in liver, brain, and cornea
3. GeneticsAutosomal recessive; ATP7B (13q14.3); more than 700 pathogenic variants reported; H1069Q (Europe) and R778L (Asia) frequent
4. EpidemiologyPrevalence about 1 in 30,000 births; carrier frequency about 1 in 90; occurs in all ethnic groups worldwide
5. PathophysiologyATP7B deficiency → decreased biliary copper excretion by hepatocytes → copper accumulation in the liver → release of free copper into the bloodstream → deposition in brain (striatum), cornea, kidney, and other organs
6. SymptomsHepatic symptoms (hepatitis to cirrhosis to acute liver failure), neurological symptoms (tremor, dystonia, dysarthria), psychiatric symptoms (personality change, psychosis)
7. SignsKayser-Fleischer ring (KF ring, cornea), hepatosplenomegaly, movement disorder (wing-beating tremor), Coombs-negative hemolytic anemia
8. ScreeningSerum ceruloplasmin measurement (decreased); serum copper; liver function tests; ophthalmologic slit-lamp examination
9. DiagnosisLeipzig scoring system; 24-hour urine copper; liver biopsy copper quantification; ATP7B molecular genetic testing
10. TreatmentD-penicillamine (copper chelator), trientine, zinc supplements; liver transplantation for acute liver failure
11. PrognosisNormal survival possible with early diagnosis and treatment; risk of death from liver failure and neurological damage if untreated or if treatment is discontinued
12. PreventionFamily screening (siblings, first-degree relatives); carrier counseling; prophylactic treatment after early diagnosis
13. ReferencesList of key PMIDs and DOIs

1. History

The history of Wilson disease begins in 1902, when the German ophthalmologist Bernhard Kayser first found a corneal pigment ring in a patient with a progressive neurological disease. In 1903 Bruno Fleischer also described a similar corneal finding, and this finding was subsequently named the 'Kayser-Fleischer ring'. In 1912, the British neurologist Samuel Alexander Kinnier Wilson systematically defined, in his paper 'Progressive lenticular degeneration', a characteristic disease involving both the liver and basal ganglia, and it later came to be called Wilson disease after his name. Abnormal copper metabolism as the cause was revealed through biochemical research in the 1940s-1950s, and in 1952 Cumings confirmed excess copper deposition in the liver and brain. In 1956, Walshe first introduced D-penicillamine as a chelation therapy, marking a turning point in treatment. In 1993, three research teams independently identified the ATP7B gene, establishing the molecular mechanism of Wilson disease. Recently, updated practice guidelines were published by international societies such as AASLD and EASL over 2022-2024, and refinement of the diagnostic system and research on new therapeutics are active.

2. Causes

The direct cause of Wilson disease is loss of function of the copper-transporting ATPase (ATP7B) due to pathogenic variants in both alleles of the ATP7B gene located on chromosome 13 (13q14.3). ATP7B is a membrane protein expressed mainly in hepatocytes and performs two important functions. First, for ceruloplasmin synthesis, it incorporates copper into apoceruloplasmin and secretes it into the blood. Second, it excretes excess copper into bile to maintain copper homeostasis in the body. When ATP7B function is lost, both pathways are impaired, so copper cannot be excreted into bile and accumulates within hepatocytes. As hepatocyte damage accumulates, free (non-ceruloplasmin-bound) copper (Non-ceruloplasmin-bound copper, NCC) is released into the bloodstream and deposits in the brain (especially basal ganglia, striatum, and thalamus), cornea, kidney, red blood cells, heart, and so on, causing organ damage. The redox activity of copper aggravating intracellular oxidative stress is also an important pathogenic factor.

3. Genetics

Wilson disease follows an autosomal recessive mode of inheritance. The ATP7B gene is located at 13q14.3 and consists of 21 exons. More than 700 pathogenic variants are currently registered in ClinVar and HGMD, and the variant types are diverse, including missense, nonsense, splice, small deletions/insertions, and large rearrangements. As important regional frequent variants, H1069Q (p.His1069Gln) accounts for about 40-70% of ATP7B variants in those of European descent, and R778L (p.Arg778Leu) is reported as the most common variant in Asia (Korea, China, Japan). The carrier (heterozygote) frequency is estimated at about 1 in 90, and the prevalence in the population is about 1 in 30,000. The disease develops in the homozygous or compound heterozygous state, and carriers are normal. The genotype-phenotype correlation is incomplete, and various clinical phenotypes such as hepatic, neurological, and mixed forms appear even in patients with the same variant. This reflects the influence of environmental factors, copper intake, and other modifier genes.

4. General epidemiology

The worldwide prevalence of Wilson disease is estimated at about 1 in 30,000 births. This is relatively common among autosomal recessive genetic diseases, with a carrier frequency of about 1 in 90. It occurs in all ethnic groups and races, and there is no difference in prevalence by sex. Clinical symptoms are uncommon before 5 years of age and in most cases appear between 5 and 35 years of age. In children it tends to present mainly with hepatic symptoms, and in adolescents and adults with neurological or psychiatric symptoms. However, many cases first manifesting in middle or old age have also been reported, so differential diagnosis regardless of age is needed. Precise data on prevalence in Korea are lacking, but considering the population size, several thousand patients are estimated to exist, and Korea-specific ATP7B variants (R778L, etc.) have been reported. For early diagnosis, international guidelines recommend screening all first-degree relatives, including siblings, of confirmed patients.

5. Pathophysiology

When biliary copper excretion from hepatocytes is blocked by loss of ATP7B function, copper goes through an initial stage in which it is stored bound to hepatic metallothionein. When this capacity is exceeded, free copper that generates reactive oxygen species accumulates in hepatocyte organelles (mitochondria, endoplasmic reticulum), causing oxidative stress, lipid peroxidation, and DNA damage, and ultimately hepatocyte death and hepatic fibrosis and cirrhosis. When liver injury progresses and exceeds hepatic storage capacity or acute hepatocellular necrosis occurs, blood free copper (Non-ceruloplasmin-bound copper, NCC) rises markedly and deposits in extrahepatic organs such as the brain, cornea, kidney, and red blood cells. In the brain, copper deposition occurs in the basal ganglia (putamen, caudate nucleus), thalamus, and cerebellum, causing neuronal damage, neurotransmitter dysfunction, and myelin degeneration. In the cornea, copper deposits in Descemet's membrane, forming the Kayser-Fleischer ring. In the kidney, tubular damage occurs.

6. Symptoms

Hepatic symptoms: Range from asymptomatic liver function abnormality to acute hepatitis, fatty liver, chronic active hepatitis, cirrhosis, and acute liver failure (Wilson disease-associated acute liver failure, poor prognosis). Acute liver failure shows a specific pattern accompanied by Coombs-negative hemolytic anemia.

Neurological symptoms: Wing-beating tremor (more marked on maintaining posture than at rest), bradykinesia, dystonia, chorea, ataxia, dysarthria, and dysphagia appear. Neurological symptoms usually manifest in the 10s-40s and progress slowly.

Psychiatric symptoms: Personality change, disinhibition, impulse control disorder, depression, anxiety, and psychosis (delusions, hallucinations) appear before or together with neurological symptoms, so patients are easily mistaken for first-visit psychiatric patients.

Others: Renal (Fanconi syndrome), joint (early osteoarthritis), cardiac (arrhythmia), and endocrine (premature amenorrhea) symptoms rarely accompany.

7. Signs

Kayser-Fleischer ring: A specific finding in which a yellow-brown to reddish-brown ring-shaped pigmentation forms from copper deposition in Descemet's membrane at the corneal periphery. It is confirmed by slit-lamp examination and is often not visible to the naked eye. It is observed in 95-99% of patients with neurological Wilson disease, but appears in only 50% or fewer in the hepatic form.

Neurological signs: Wing-beating tremor, dystonic posture, ataxic gait, and cranial nerve symptoms (dysarthria, reduced facial expression) are found.

Hepatic findings: Hepatosplenomegaly, ascites, jaundice, and abdominal wall collateral circulation (with progression of cirrhosis) are observed.

Blood tests: Decreased serum ceruloplasmin (<0.2 g/L), decreased serum copper (decreased ceruloplasmin-bound copper, but free copper is increased), increased 24-hour urine copper (>100 µg/day), liver function abnormalities, Coombs-negative hemolytic anemia.

Brain MRI: T2/FLAIR hyperintensity in the basal ganglia (putamen, caudate nucleus), thalamus, and brainstem, and the 'face of the giant panda' sign (a specific finding of the midbrain tegmentum) may be observed.

8. Screening

The most important screening test for Wilson disease is serum ceruloplasmin measurement. The normal value is 0.2-0.4 g/L, and in Wilson disease it is mostly decreased to below 0.2 g/L. However, ceruloplasmin is an acute-phase reactant and can normalize as a false result in hepatitis, pregnancy, and oral contraceptive use, so caution is needed. Total serum copper decreases because of decreased ceruloplasmin, but free copper (NCC) is increased, so be careful when interpreting it alone. A 24-hour urine copper excretion of 100 µg/day or more strongly suggests Wilson disease. Screening for Wilson disease is essential in patients with unexplained elevated liver enzymes on liver function tests and in patients with neuropsychiatric abnormalities before age 30. Screening is performed in all siblings and first-degree relatives of confirmed patients.

9. Diagnosis

Leipzig scoring system (2001): Items such as the presence of a Kayser-Fleischer ring, neuropsychiatric symptoms, serum ceruloplasmin, 24-hour urine copper, hepatic copper content, Coombs-negative hemolytic anemia, and ATP7B variants are scored, and a total of 4 or more points is classified as definitive diagnosis and 3 points as suspected.

Liver biopsy: A hepatic copper content of 250 µg/g dry weight or more (normal <50 µg/g) strongly supports Wilson disease. Liver histopathology shows fatty liver, glycogenated nuclei, necrosis, fibrosis, and rhodanine-stained copper deposition.

Molecular genetic testing: Sequencing of all exons of the ATP7B gene and deletion/duplication testing are performed to confirm variants in both alleles. The diagnosis is confirmed when both variants are identified. Frequent variants such as R778L in Asian patients and H1069Q in European patients are checked first.

Brain MRI: Essential for confirming abnormal signal in the basal ganglia in patients with neurological symptoms and for differential diagnosis. Slit-lamp examination is essential for confirming the Kayser-Fleischer ring, and referral to an experienced ophthalmologist is needed.

10. Treatment

Copper chelation therapy: D-penicillamine is the longest-used chelating agent and promotes urinary copper excretion. It is effective for initial treatment, but caution is needed because paradoxical initial worsening occurs in about 50% of patients with neurological symptoms. Side effects include nephrotic syndrome, lupus-like reaction, bone marrow suppression, and skin changes. Trientine has fewer side effects than D-penicillamine and is used as a first-line agent or as an alternative in patients intolerant of D-penicillamine.

Zinc supplements: Zinc salts (zinc acetate, etc.) block dietary copper absorption through induction of enterocyte metallothionein and thereby reduce blood copper. The copper-removing effect is slower than with chelating agents but side effects are fewer, so they are preferred for presymptomatic patients, maintenance therapy, and treatment during pregnancy.

Liver transplantation: Liver transplantation is needed in patients with acute liver failure or end-stage cirrhosis not improved by chelation therapy. After liver transplantation, the ATP7B enzyme is supplied and copper metabolism normalizes. The effect of liver transplantation on neurological symptoms is controversial, but some studies have reported improvement of neurological symptoms after transplantation even in neurological-form patients in whom chelation therapy failed.

11. Prognosis

If Wilson disease is diagnosed early and treatment is started, a normal or near-normal lifespan is possible. As long as treatment adherence is maintained, recovery of liver function, improvement of neurological symptoms, and disappearance of the Kayser-Fleischer ring are possible. However, if treatment is stopped or taken irregularly, acute liver failure, neurological deterioration, and death can occur, and many deaths after treatment discontinuation have been reported, so lifelong treatment is essential. If advanced cirrhosis is already present at diagnosis, there is no effective treatment other than liver transplantation. In neurological Wilson disease, initial worsening after starting chelation therapy (D-penicillamine) may occur, or complete recovery may be difficult when organ damage is severe. Overall, Wilson disease belongs to the group of diseases with the best prognosis among early-onset rare diseases when appropriately treated.

12. Prevention

The most effective prevention of Wilson disease is early familial screening to diagnose before symptom onset and start preventive treatment. Screening including serum ceruloplasmin, 24-hour urinary copper, liver function tests, slit-lamp examination, and ATP7B gene testing is performed in all siblings and children of confirmed patients. In carriers diagnosed before symptom onset, starting zinc supplementation or chelation therapy preventively can prevent liver damage and neurological damage. Avoiding excessive intake of copper-rich foods (liver, oysters, nuts, chocolate, mushrooms, etc.) and caution regarding drinking tap water with high copper content (copper piping) are recommended. Prenatal diagnosis is possible by ATP7B molecular genetic testing in families that already have an affected child.

13. References

  1. Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain. 1912;34(1):295-509. DOI: 10.1093/brain/34.4.295
  2. Bull PC, et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993;5(4):327-337. PMID: 8298639
  3. Ferenci P, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23(3):139-142. PMID: 12955875
  4. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47(6):2089-2111. PMID: 18506894
  5. Socha P, et al. Wilson's disease in children. J Hepatol. 2018;69(3):620-629. PMID: 29940290
  6. Stremmel W, et al. Wilson disease: clinical presentation, treatment, and survival. Ann Intern Med. 1991;115(9):720-726. PMID: 1929033
  7. Członkowska A, et al. Wilson disease. Nat Rev Dis Primers. 2018;4(1):21. PMID: 30190489
  8. Sandahl TD, et al. Current Management of Neurological Wilson's Disease. Cells. 2025;14(8):561. DOI: 10.3390/cells14080561
  9. Schilsky ML. Wilson Disease: Diagnosis, Treatment, and Follow-Up. Clin Liver Dis. 2017;21(4):755-767. PMID: 28987255
  10. European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol. 2012;56(3):671-685. PMID: 22300508